AAAAAA

   
Results: 1-18 |
Results: 18
Surfactant alteration and replacement in acute respiratory distress syndrome
Authors: Gunther, A Ruppert, C Schmidt, R Markart, P Grimminger, F Walmrath, D Seeger, W
Citation: A. Gunther et al., Surfactant alteration and replacement in acute respiratory distress syndrome, RESPIR RES, 2(6), 2001, pp. 353-NIL_2
Coaerosolization of phosphodiesterase inhibitors markedly enhances the pulmonary vasodilatory response to inhaled iloprost in experimental pulmonary hypertension - Maintenance of lung selectivity
Authors: Schermuly, RT Krupnik, E Tenor, H Schudt, C Weissmann, N Rose, F Grimminger, F Seeger, W Walmrath, D Ghofrani, HA
Citation: Rt. Schermuly et al., Coaerosolization of phosphodiesterase inhibitors markedly enhances the pulmonary vasodilatory response to inhaled iloprost in experimental pulmonary hypertension - Maintenance of lung selectivity, AM J R CRIT, 164(9), 2001, pp. 1694-1700
Alteration of fatty acid profiles in different pulmonary surfactant phospholipids in acute respiratory distress syndrome and severe pneumonia
Authors: Schmidt, R Meier, U Yabut-Perez, M Walmrath, D Grimminger, F Seeger, W Gunther, A
Citation: R. Schmidt et al., Alteration of fatty acid profiles in different pulmonary surfactant phospholipids in acute respiratory distress syndrome and severe pneumonia, AM J R CRIT, 163(1), 2001, pp. 95-100
Urodilatin, a natriuretic peptide stimulating particulate guanylate cyclase, and the phosphodiesterase 5 inhibitor dipyridamole attenuate experimental pulmonary hypertension synergism upon coapplication
Authors: Schermuly, RT Weissmann, N Enke, B Ghofrani, HA Forssmann, WG Grimminger, F Seeger, W Walmrath, D
Citation: Rt. Schermuly et al., Urodilatin, a natriuretic peptide stimulating particulate guanylate cyclase, and the phosphodiesterase 5 inhibitor dipyridamole attenuate experimental pulmonary hypertension synergism upon coapplication, AM J RESP C, 25(2), 2001, pp. 219-225
Combination of nonspecific PDE inhibitors with inhaled prostacyclin in experimental pulmonary hypertension
Authors: Schermuly, RT Roehl, A Weissmann, N Ghofrani, HA Leuchte, H Grimminger, F Seeger, W Walmrath, D
Citation: Rt. Schermuly et al., Combination of nonspecific PDE inhibitors with inhaled prostacyclin in experimental pulmonary hypertension, AM J P-LUNG, 281(6), 2001, pp. L1361-L1368
Conebulization of surfactant and urokinase restores gas exchange in perfused lungs with alveolar fibrin formation
Authors: Schermuly, RT Gunther, A Ermert, M Ermert, L Ghofrani, HA Weissmann, N Grimminger, F Seeger, W Walmrath, D
Citation: Rt. Schermuly et al., Conebulization of surfactant and urokinase restores gas exchange in perfused lungs with alveolar fibrin formation, AM J P-LUNG, 280(4), 2001, pp. L792-L800
Volume-dependent compliance and ventilation-perfusion mismatch in surfactant-depleted isolated rabbit lungs
Authors: Mols, G Hermle, G Schubert, J Miekisch, W Benzing, A Lichtwarck-Aschoff, M Geiger, K Walmrath, D Gutmann, J
Citation: G. Mols et al., Volume-dependent compliance and ventilation-perfusion mismatch in surfactant-depleted isolated rabbit lungs, CRIT CARE M, 29(1), 2001, pp. 144-151
Protection against gas exchange abnormalities by pre-aerosolized PGE(1), iloprost and nitroprusside in lung ischemia-reperfusion
Authors: Lockinger, A Schutte, H Walmrath, D Seeger, W Grimminger, F
Citation: A. Lockinger et al., Protection against gas exchange abnormalities by pre-aerosolized PGE(1), iloprost and nitroprusside in lung ischemia-reperfusion, TRANSPLANT, 71(2), 2001, pp. 185-193
Alveolar fibrin formation caused by enhanced procoagulant and depressed fibrinolytic capacities in severe pneumonia - Comparison with the acute respiratory distress syndrome
Authors: Gunther, A Mosavi, P Heinemann, S Ruppert, C Muth, H Markart, P Grimminger, F Walmrath, D Temmesfeld-Wollbruck, B Seeger, W
Citation: A. Gunther et al., Alveolar fibrin formation caused by enhanced procoagulant and depressed fibrinolytic capacities in severe pneumonia - Comparison with the acute respiratory distress syndrome, AM J R CRIT, 161(2), 2000, pp. 454-462
Differential impact of ultrasonically nebulized versus tracheal-instilled surfactant on ventilation-perfusion (VA/Q) mismatch in a model of acute lung injury
Authors: Schermuly, RT Gunther, A Weissmann, N Ghofrani, HA Seeger, W Grimminger, F Walmrath, D
Citation: Rt. Schermuly et al., Differential impact of ultrasonically nebulized versus tracheal-instilled surfactant on ventilation-perfusion (VA/Q) mismatch in a model of acute lung injury, AM J R CRIT, 161(1), 2000, pp. 152-159
PAF-induced synthesis of tetraenoic and pentaenoic leukotrienes in the isolated rabbit lung
Authors: Grimminger, F Mayer, K Kiss, L Walmrath, D Seeger, W
Citation: F. Grimminger et al., PAF-induced synthesis of tetraenoic and pentaenoic leukotrienes in the isolated rabbit lung, AM J P-LUNG, 278(2), 2000, pp. L268-L275
Enhanced tissue factor pathway activity and fibrin turnover in the alveolar compartment of patients with interstitial lung disease
Authors: Gunther, A Mosavi, P Ruppert, C Heinemann, S Temmesfeld, B Velcovsky, HG Morr, H Grimminger, F Walmrath, D Seeger, W
Citation: A. Gunther et al., Enhanced tissue factor pathway activity and fibrin turnover in the alveolar compartment of patients with interstitial lung disease, THROMB HAEM, 83(6), 2000, pp. 853-860
Inhalative strategies for treatment of pulmonary hypertension and gas exchange disturbances in sepsis and chronic pulmonary hypertension
Authors: Grimminger, F Rose, F Ghofrani, HA Schermuly, RT Weissmann, N Olschewski, H Walmrath, D Seeger, W
Citation: F. Grimminger et al., Inhalative strategies for treatment of pulmonary hypertension and gas exchange disturbances in sepsis and chronic pulmonary hypertension, Z KARDIOL, 89(6), 2000, pp. 477-484
Subthreshold doses of specific phosphodiesterase type 3 and 4 inhibitors enhance the pulmonary vasodilatory response to nebulized prostacyclin with improvement in gas exchange
Authors: Schermuly, RT Roehl, A Weissmann, N Ghofrani, HA Schudt, C Tenor, H Grimminger, F Seeger, W Walmrath, D
Citation: Rt. Schermuly et al., Subthreshold doses of specific phosphodiesterase type 3 and 4 inhibitors enhance the pulmonary vasodilatory response to nebulized prostacyclin with improvement in gas exchange, J PHARM EXP, 292(2), 2000, pp. 512-520
Low-dose systemic phosphodiesterase inhibitors amplify the pulmonary vasodilatory response to inhaled prostacyclin in experimental pulmonary hypertension
Authors: Schermuly, RT Ghofrani, HA Enke, B Weissmann, N Grimminger, F Seeger, W Schudt, C Walmrath, D
Citation: Rt. Schermuly et al., Low-dose systemic phosphodiesterase inhibitors amplify the pulmonary vasodilatory response to inhaled prostacyclin in experimental pulmonary hypertension, AM J R CRIT, 160(5), 1999, pp. 1500-1506
Ventilation-perfusion mismatch after lung ischemia-reperfusion - Protective effect of nitric oxide
Authors: Hermle, G Schutte, H Walmrath, D Geiger, K Seeger, W Grimminger, F
Citation: G. Hermle et al., Ventilation-perfusion mismatch after lung ischemia-reperfusion - Protective effect of nitric oxide, AM J R CRIT, 160(4), 1999, pp. 1179-1187
Prostacyclin enhances stretch-induced surfactant secretion in alveolar epithelial type II cells
Authors: Rose, F Zwick, K Ghofrani, HA Sibelius, U Seeger, W Walmrath, D Grimminger, F
Citation: F. Rose et al., Prostacyclin enhances stretch-induced surfactant secretion in alveolar epithelial type II cells, AM J R CRIT, 160(3), 1999, pp. 846-851
Inhaled prostacyclin and iloprost in severe pulmonary hypertension secondary to lung fibrosis
Authors: Olschewski, H Ghofrani, HA Walmrath, D Schermuly, R Temmesfeld-Wollbruck, B Grimminger, F Seeger, W
Citation: H. Olschewski et al., Inhaled prostacyclin and iloprost in severe pulmonary hypertension secondary to lung fibrosis, AM J R CRIT, 160(2), 1999, pp. 600-607
Risultati: 1-18 |